HomeCompareRVXCF vs ORCC

RVXCF vs ORCC: Dividend Comparison 2026

RVXCF yields 2500.00% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RVXCF wins by $80609755877.35M in total portfolio value
10 years
RVXCF
RVXCF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full RVXCF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — RVXCF vs ORCC

📍 RVXCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRVXCFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RVXCF + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RVXCF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RVXCF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, RVXCF beats the other by $63,520,143,069,579,940.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RVXCF + ORCC for your $10,000?

RVXCF: 50%ORCC: 50%
100% ORCC50/50100% RVXCF
Portfolio after 10yr
$40304877938.69M
Annual income
$37,364,790,040,929,380.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

RVXCF
No analyst data
Altman Z
-94.1
Piotroski
1/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RVXCF buys
0
ORCC buys
0
No recent congressional trades found for RVXCF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRVXCFORCC
Forward yield2500.00%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$80609755877.37M$21.4K
Annual income after 10y$74,729,580,081,858,750.00$1.04
Total dividends collected$80198875900.38M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: RVXCF vs ORCC ($10,000, DRIP)

YearRVXCF PortfolioRVXCF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$260,700$250,000.00$11,190$489.61+$249.5KRVXCF
2$6,370,070$6,091,121.50$12,229$256.01+$6.36MRVXCF
3$145,912,632$139,096,656.81$13,216$130.74+$145.90MRVXCF
4$3,133,830,814$2,977,704,297.75$14,207$66.02+$3133.82MRVXCF
5$63,122,812,060$59,769,613,088.96$15,234$33.17+$63122.80MRVXCF
6$1,192,683,724,131$1,125,142,315,226.76$16,317$16.62+$1192683.71MRVXCF
7$21,144,559,711,004$19,868,388,126,183.19$17,468$8.32+$21144559.69MRVXCF
8$351,818,906,448,043$329,194,227,557,269.44$18,695$4.16+$351818906.43MRVXCF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$20,006$2.08+$5495491397.65MRVXCF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$21,407$1.04+$80609755877.35MRVXCF

RVXCF vs ORCC: Complete Analysis 2026

RVXCFStock

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Full RVXCF Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this RVXCF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RVXCF vs SCHDRVXCF vs JEPIRVXCF vs ORVXCF vs KORVXCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.